


Author's Accepted Manuscript

Disease-Specific Hashtags and the Creation of
Twitter Medical Communities in Hematology and
Oncology Disease-specific Hashtags in Hematology
and Oncology

Naveen Pemmaraju, Michael A. Thompson,
Muzaffar Qazilbash



PII: S0037-1963(17)30109-9

DOI: <http://dx.doi.org/10.1053/j.seminhematol.2017.08.004>

Reference: YSHEM50931

To appear in: *Seminars in Hematology*

Cite this article as: Naveen Pemmaraju, Michael A. Thompson and Muzaffar Qazilbash, Disease-Specific Hashtags and the Creation of Twitter Medical Communities in Hematology and Oncology Disease-specific Hashtags in Hematology and Oncology, *Seminars in Hematology*, <http://dx.doi.org/10.1053/j.seminhematol.2017.08.004>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Disease-Specific Hashtags and the Creation of Twitter Medical Communities in Hematology and Oncology

Authors: Naveen Pemmaraju^{1*}, Michael A. Thompson², Muzaffar Qazilbash³

Author Affiliations:

¹University of Texas, MD Anderson Cancer Center; Department of Leukemia, Houston TX, @doctorpemm

²Aurora Research Institute, Aurora Health Care; Milwaukee, WI @mtmdphd

³University of Texas MD Anderson Cancer Center, Dept of Stem Cell Transplant, Houston TX, @Transplant_Doc

Running title: Disease-specific Hashtags in Hematology and Oncology

Key Words: Social media, Twitter, disease-specific hashtag, organization

Authorship contributions: NP, MAT, MQ each contributing to writing the manuscript and approved the final manuscript prior to publication.

Disclosures/conflicts of interest:

NP: Research/Grant support: Affymetrix, SagerStrong Foundation.
Honorarium/Consulting and/or Research & Clinical trial support: Novartis, LFB, Incyte, Stemline, Cellectis, Abbvie, Roche Diagnostics

MAT: Associate Editor, JCO CCI

Takeda/Millennium Multiple Myeloma Registry - 2016-

VIA Oncology, Co-Chair Medical Oncology Myeloma Committee - 2015-present

VIA Oncology, Co-Chair Medical Oncology Indolent Lymphoma Committee - 2015-present

AIM Specialty Health – Advisory Board - 2015-present

Advisory Board – BMS (Elotuzumab) - 07/12/15

Download English Version:

<https://daneshyari.com/en/article/8734819>

Download Persian Version:

<https://daneshyari.com/article/8734819>

[Daneshyari.com](https://daneshyari.com)